AR070992A1 - Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 - Google Patents
Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1Info
- Publication number
- AR070992A1 AR070992A1 ARP090100985A ARP090100985A AR070992A1 AR 070992 A1 AR070992 A1 AR 070992A1 AR P090100985 A ARP090100985 A AR P090100985A AR P090100985 A ARP090100985 A AR P090100985A AR 070992 A1 AR070992 A1 AR 070992A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- nrarb
- aryl
- alkoxy
- Prior art date
Links
- 108020005497 Nuclear hormone receptor Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 102000006255 nuclear receptors Human genes 0.000 title 1
- 108020004017 nuclear receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 16
- 229910003827 NRaRb Inorganic materials 0.000 abstract 13
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 9
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 8
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 8
- 229910052736 halogen Inorganic materials 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 7
- 125000001188 haloalkyl group Chemical group 0.000 abstract 6
- 125000001424 substituent group Chemical group 0.000 abstract 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000006557 (C2-C5) alkylene group Chemical group 0.000 abstract 2
- -1 C1-10 arylalkylene Chemical group 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 abstract 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- FQUYSHZXSKYCSY-UHFFFAOYSA-N 1,4-diazepane Chemical compound C1CNCCNC1 FQUYSHZXSKYCSY-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 abstract 1
- 125000002393 azetidinyl group Chemical group 0.000 abstract 1
- 238000004177 carbon cycle Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001577 copolymer Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000004001 thioalkyl group Chemical group 0.000 abstract 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Reivindicacion 1: Compuestos de formula (1) en la que R1 representa un grupo fenilo o un grupo naftilo, pudiendo estar estos dos grupos sustituidos opcionalmente con uno o varios átomos o grupos elegidos independientemente los unos de los otros entre los átomos o grupos siguientes halogeno, alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, tioalquilo C1-10, -S(O)alquilo C1-10, -S(O)2alquilo C1-10, hidroxilo, ciano, nitro, hidroxialquileno C1-10, NRaRb-alquileno C1-10, alcoxi C1-10-alquileno C1-10-oxi, NRaRb, CONRaRb, SO2NRaRb, NRcCORd, OC(O)NRaRb, OCO-alquilo C1-10, NRcC(O)ORe, NRcSO2Re, arilalquileno C1-10, arilo o heteroarilo monocíclico, estando el arilo o el heteroarilo monocíclico sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, oxo, nitro, ciano o OCOalquilo C1-10; X representa de 1 a 4 sustituyentes idénticos o diferentes el uno del otro, elegidos entre halogeno, alquilo C1-10, alcoxi C1-10, NRaRb, ciano, nitro, pudiendo estar el alquilo C1-10 sustituido opcionalmente con uno o varios grupos elegidos entre un halogeno, alcoxi C1-10, haloalcoxi C1-10, NRaRb o hidroxilo; R2 y R3 representan, independientemente el uno del otro, un átomo de hidrogeno, un grupo alquilo C1-10, estando este grupo sustituido opcionalmente con un grupo Rf; un grupo arilo, sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro o ciano; R2 y X pueden formar juntos con los átomos de carbono a los que están unidos un ciclo carbonado de 5 a 7 átomos de carbono; R4 representa un átomo de hidrogeno, un grupo alquilo C1-10, estando este grupo sustituido opcionalmente con un grupo Rf; un grupo arilo, sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro, ciano, alquil C1-10-CO-, CONRaRb, -NRcCORd, OC(O)NRaRb, OCOalquilo C1-10, NRcC(O)ORe o arilo, estando el arilo sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro o ciano; Ra y Rb representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-10, arilalquileno C1-10 o arilo, o Ra y Rb forman juntos, con el átomo de nitrogeno al que están unidos, un grupo azetidina, pirrolidina, piperidina, azepina, morfolina, tiomorfolina, piperacina, homopiperacina, estando este grupo sustituido opcionalmente con un grupo alquilo C1-10, arilo o arilalquileno C1-10; Rc y Rd representan, independientemente el uno del otro, un átomo de hidrogeno o un grupo alquilo C1-10, arilalquileno C1-10, arilo; o Rc y Rd forman juntos un grupo alquileno C2-5; Re representa un grupo alquilo C1-10, arilalquileno C1-10, arilo; o Rc y Re forman juntos un grupo alquileno C2-5; Rf representa un átomo de halogeno, un grupo alcoxi C1-10, haloalcoxi C1-10, hidroxilo, ciano, NRaRb, C(O)NRaRb, NRcCORd, OC(O)NRaRb, OCOalquilo C1-10, NRcCOORe, SO2NRaRb, NRcSO2Re, arilalquileno C1-10, arilo, estando el arilo sustituido opcionalmente con uno o varios sustituyentes elegidos entre un halogeno, un grupo alquilo C1-10, haloalquilo C1-10, alcoxi C1-10, haloalcoxi C1-10, NRaRb, hidroxilo, nitro, ciano o OCOalquilo C1-10, en el estado de base o de sal de adicion a un ácido.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0801580A FR2928921B1 (fr) | 2008-03-21 | 2008-03-21 | Derives polysubstitues de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines, leur preparation et leur application en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR070992A1 true AR070992A1 (es) | 2010-05-19 |
Family
ID=39764893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP090100985A AR070992A1 (es) | 2008-03-21 | 2009-03-19 | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US8148370B2 (es) |
| EP (1) | EP2262803B1 (es) |
| JP (1) | JP5508383B2 (es) |
| KR (1) | KR20100129774A (es) |
| CN (1) | CN102036988B (es) |
| AR (1) | AR070992A1 (es) |
| AU (1) | AU2009253231B2 (es) |
| BR (1) | BRPI0908999A8 (es) |
| CA (1) | CA2718953C (es) |
| CL (1) | CL2009000695A1 (es) |
| CO (1) | CO6300865A2 (es) |
| CY (1) | CY1113549T1 (es) |
| DK (1) | DK2262803T3 (es) |
| EA (1) | EA018266B1 (es) |
| ES (1) | ES2397931T3 (es) |
| FR (1) | FR2928921B1 (es) |
| HR (1) | HRP20130029T1 (es) |
| IL (1) | IL208248A0 (es) |
| MA (1) | MA32246B1 (es) |
| ME (2) | ME01469B (es) |
| MX (1) | MX2010010259A (es) |
| NZ (1) | NZ588081A (es) |
| PE (1) | PE20091818A1 (es) |
| PL (1) | PL2262803T3 (es) |
| PT (1) | PT2262803E (es) |
| RS (1) | RS52652B (es) |
| SI (1) | SI2262803T1 (es) |
| TW (1) | TW201000477A (es) |
| UY (1) | UY31727A (es) |
| WO (1) | WO2009144391A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
| FR2928924B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 6-heteroaryle-imidazo°1,2-a! pyridines, leur preparation et leur application en therapeutique |
| FR2953520B1 (fr) * | 2009-12-04 | 2011-11-25 | Sanofi Aventis | Derives de diphenyl-pyrazolopyridines, leur preparation et leur application en therapeutique |
| TW201718581A (zh) | 2015-10-19 | 2017-06-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| SG10202004618TA (en) | 2015-11-19 | 2020-06-29 | Incyte Corp | Heterocyclic compounds as immunomodulators |
| US20170174671A1 (en) | 2015-12-17 | 2017-06-22 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| MA45116A (fr) | 2016-05-26 | 2021-06-02 | Incyte Corp | Composés hétérocycliques comme immunomodulateurs |
| ES2927984T3 (es) | 2016-06-20 | 2022-11-14 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| US20180057486A1 (en) | 2016-08-29 | 2018-03-01 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018119221A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| EP3558963B1 (en) | 2016-12-22 | 2022-03-23 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| MX391981B (es) | 2016-12-22 | 2025-03-21 | Incyte Corp | Derivados de benzooxazol como inmunomoduladores. |
| ES2929193T3 (es) | 2016-12-22 | 2022-11-25 | Incyte Corp | Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1 |
| SMT202300065T1 (it) | 2018-03-30 | 2023-05-12 | Incyte Corp | Composti eterociclici come immunomodulatori |
| PL3790877T3 (pl) | 2018-05-11 | 2023-06-12 | Incyte Corporation | Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1 |
| WO2021030162A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| IL291471B2 (en) | 2019-09-30 | 2025-04-01 | Incyte Corp | Pyrimido[3,2–D]pyrimidine compounds as immunomodulators |
| CN114829366A (zh) | 2019-11-11 | 2022-07-29 | 因赛特公司 | Pd-1/pd-l1抑制剂的盐及结晶形式 |
| TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式 |
| WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2903105A1 (fr) * | 2006-07-03 | 2008-01-04 | Sanofi Aventis Sa | Derives de 2-benzoyl-imidazopyridines, leur preparation et leur application en therapeutique |
| FR2903106B1 (fr) * | 2006-07-03 | 2010-07-30 | Sanofi Aventis | Utilisations de 2-benzoyl-imidazopyridines en therapeutique |
| FR2903107B1 (fr) * | 2006-07-03 | 2008-08-22 | Sanofi Aventis Sa | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique |
| FR2906250B1 (fr) * | 2006-09-22 | 2008-10-31 | Sanofi Aventis Sa | Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique |
| FR2928923B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives polysubstitues de 2-heteroaryl-6-phenyl-imidazo °1,2-a!pyridines, leur preparation et leur application en therapeutiques |
| FR2928922B1 (fr) * | 2008-03-21 | 2010-04-23 | Sanofi Aventis | Derives de 2-aryl-6-phenyl-imidazo°1,2-a!pyridines polysubstitues, leur preparation et leur application en therapeutique |
-
2008
- 2008-03-21 FR FR0801580A patent/FR2928921B1/fr not_active Expired - Fee Related
-
2009
- 2009-03-19 AR ARP090100985A patent/AR070992A1/es not_active Application Discontinuation
- 2009-03-19 PE PE2009000415A patent/PE20091818A1/es not_active Application Discontinuation
- 2009-03-20 MX MX2010010259A patent/MX2010010259A/es active IP Right Grant
- 2009-03-20 UY UY0001031727A patent/UY31727A/es not_active Application Discontinuation
- 2009-03-20 EP EP09754041A patent/EP2262803B1/fr active Active
- 2009-03-20 KR KR1020107023410A patent/KR20100129774A/ko not_active Withdrawn
- 2009-03-20 ES ES09754041T patent/ES2397931T3/es active Active
- 2009-03-20 ME MEP-2013-4A patent/ME01469B/me unknown
- 2009-03-20 CL CL2009000695A patent/CL2009000695A1/es unknown
- 2009-03-20 JP JP2011500258A patent/JP5508383B2/ja not_active Expired - Fee Related
- 2009-03-20 CN CN2009801185642A patent/CN102036988B/zh not_active Expired - Fee Related
- 2009-03-20 HR HRP20130029AT patent/HRP20130029T1/hr unknown
- 2009-03-20 NZ NZ588081A patent/NZ588081A/en not_active IP Right Cessation
- 2009-03-20 DK DK09754041.3T patent/DK2262803T3/da active
- 2009-03-20 BR BRPI0908999A patent/BRPI0908999A8/pt not_active IP Right Cessation
- 2009-03-20 AU AU2009253231A patent/AU2009253231B2/en not_active Ceased
- 2009-03-20 RS RS20130008A patent/RS52652B/sr unknown
- 2009-03-20 SI SI200930480T patent/SI2262803T1/sl unknown
- 2009-03-20 CA CA2718953A patent/CA2718953C/fr not_active Expired - Fee Related
- 2009-03-20 TW TW098109237A patent/TW201000477A/zh unknown
- 2009-03-20 EA EA201071110A patent/EA018266B1/ru not_active IP Right Cessation
- 2009-03-20 PT PT97540413T patent/PT2262803E/pt unknown
- 2009-03-20 WO PCT/FR2009/000297 patent/WO2009144391A1/fr not_active Ceased
- 2009-03-20 ME MEP-2010-151A patent/ME01098B/me unknown
- 2009-03-20 PL PL09754041T patent/PL2262803T3/pl unknown
-
2010
- 2010-09-14 US US12/881,805 patent/US8148370B2/en not_active Expired - Fee Related
- 2010-09-19 IL IL208248A patent/IL208248A0/en unknown
- 2010-09-21 CO CO10116606A patent/CO6300865A2/es not_active Application Discontinuation
- 2010-10-19 MA MA33272A patent/MA32246B1/fr unknown
-
2013
- 2013-01-17 CY CY20131100052T patent/CY1113549T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR070992A1 (es) | Derivados de 2-aril-6-fenil-inidazo[1,2a]piridinas, su preparacion, composiciones farmaceuticas y su uso en enfermedades que implican los receptores nucleares nurr-1 | |
| AR070995A1 (es) | Derivados polisustituidos de 6-heteroaril-imidazo[1,2-a]piridina,composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1,tales como enfe | |
| AR062897A1 (es) | Derivados de 2-aril-6-fenil-imidazo[1, 2-a]piridinas, su preparacion, composicion farmaceutica que los comprende y su empleo en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por los receptores not. | |
| AR070993A1 (es) | Derivados polisustituidos de 2-aril-6-fenil-imidazo[1,2-a]piridinas, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales como | |
| AR070994A1 (es) | Derivados polisustituidos de 2-heteroaril-6-fenil-imidazo[1,2-a]piridina, composiciones farmaceuticas que los contienen, proceso de preparacion de los mismos, intermediarios de sintesis y uso de los mismos en el tratamiento o prevencion de enfermedades que implican receptores nucleares nurr-1, tales | |
| ECSP099395A (es) | Nuevos derivados de los ácidos amino-nicotínico y amino-isonicotínico | |
| AR058198A1 (es) | Derivados de morfolina y composiciones farmaceuticas | |
| AR063804A1 (es) | Compuestos de azoniabiciclo[2.2.2]octano | |
| CO5611126A2 (es) | Derivados de indolinona utiles como inhibidores de la proteina cinasa | |
| AR055878A1 (es) | Derivados de ciclopropanocarboxamida | |
| ECSP077215A (es) | Derivados de n-(1h-indolil)-1h-indol-2-carboxamidas, su preparación y su aplicación en terapéutica | |
| AR020165A1 (es) | Derivados de pirimidinas sustituidas, su procedimiento de preparacion, composiciones farmaceuticas que las contienen y el uso de los mismos para la preparacion de medicamentos | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
| AR065863A1 (es) | Derivados de imidazolidinona | |
| AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
| AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
| AR058010A1 (es) | Derivados biciclicos como inhibidores de p38 y composicion farmaceutica en base al compuesto | |
| CO6150038A1 (es) | Nuevos derivados de diosmetina su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR077301A1 (es) | Derivados de 2-carboxamida-7-piperazinil-benzofurano como antagonistas de 5-ht1a y 5-ht1b | |
| AR078776A1 (es) | Derivados de (1,1,1,3,3,3-hexafluoro-2-hidroxipropan-2-il)-fenilo | |
| AR069813A1 (es) | Derivados de 2- amino-pirimidina, una composicion farmaceutica, un metodo de preparacion del compuesto y uso del mismo para preparar un medicamento | |
| CO5690593A2 (es) | Nuevos derivados de pirimidin 2-amina | |
| AR043487A1 (es) | Heterociclos fusionados de pirimidina y usos de los mismos | |
| ES2606839T3 (es) | Tetraaza-ciclopenta[a]indenilo y su uso como moduladores alostéricos positivos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |